在早期研究中，巨大的不可溶的Aβ斑块被认为是引发患者症状的头号元凶。科学家们普遍认为，这些斑块的形成是AD的核心病理特征，也是导致认知功能障碍的主要原因。因此，大量的研究资源和精力被投入到针对Aβ斑块的治疗策略中，希望能够通过清除这些斑块来改善患者的 ...

Aβ的“前身”是正常存在于神经元中的淀粉样前体蛋白（APP），在某些情况下被蛋白酶错误切割而产生。在AD患者的大脑中，Aβ的生成源源不断地 ...

The presented trial results, especially in MCI patients, are promising, particularly as Alzheon is targeting a subset of ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to such cells in non-immunized controls, regardless of whether the treatment was ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state ...

CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate update.

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for ...

Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug ...

It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Since 2005, BioArctic has a long ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer ...